Display options
Cite
Tsutsumi N, Kohnoe S, Sonoda H, et al. Protein-bound polysaccharide-K reduces colitic tumors and improves survival of inflammatory bowel disease in vivo. Oncol Lett. 2011;2(5):791-796doi: 10.3892/ol.2011.336.
Tsutsumi, N., Kohnoe, S., Sonoda, H., Guntani, A., Rikimaru, T., Taguchi, K. I., Tomikawa, M., Kakeji, Y., Nakashima, H., & Maehara, Y. (2011). Protein-bound polysaccharide-K reduces colitic tumors and improves survival of inflammatory bowel disease in vivo. Oncology letters, 2(5), 791-796. https://doi.org/10.3892/ol.2011.336
Tsutsumi, Norifumi, et al. "Protein-bound polysaccharide-K reduces colitic tumors and improves survival of inflammatory bowel disease in vivo." Oncology letters vol. 2,5 (2011): 791-796. doi: https://doi.org/10.3892/ol.2011.336
Tsutsumi N, Kohnoe S, Sonoda H, Guntani A, Rikimaru T, Taguchi KI, Tomikawa M, Kakeji Y, Nakashima H, Maehara Y. Protein-bound polysaccharide-K reduces colitic tumors and improves survival of inflammatory bowel disease in vivo. Oncol Lett. 2011 Sep 01;2(5):791-796. doi: 10.3892/ol.2011.336. Epub 2011 Jul 04. PMID: 22866128; PMCID: PMC3408101.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2011 Sep 01;2(5):791-796. doi: 10.3892/ol.2011.336. Epub 2011 Jul 04.

Protein-bound polysaccharide-K reduces colitic tumors and improves survival of inflammatory bowel disease in vivo.

Oncology letters

Norifumi Tsutsumi, Shunji Kohnoe, Hideto Sonoda, Atsushi Guntani, Tatsuya Rikimaru, Ken-Ichi Taguchi, Morimasa Tomikawa, Yoshihiro Kakeji, Hideaki Nakashima, Yoshihiko Maehara

Affiliations

  1. Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.

PMID: 22866128 PMCID: PMC3408101 DOI: 10.3892/ol.2011.336

Abstract

Protein-bound polysaccharide-K (PSK) is a biological response modifier that possesses antitumor effects against various tumors. Although an inflammatory response has been considered to play an important role in the development of colorectal cancer, the anti-inflammatory effect of PSK has yet to be elucidated. An inflammatory bowel disease (IBD)-induced colorectal tumor model with 1.2-dimethyl hydrazine (DMH) and dextran sodium sulfate (DSS) was used to examine the effects of PSK on tumor suppression and survival. Although 90% of the mice that were not treated with PSK developed colitic tumors, oral administration of PSK suppressed tumor formation by less than 30%. Although deaths associated with DSS-induced melena were observed, PSK significantly reduced mortality. In conclusion, the present study showed that PSK not only suppressed colorectal tumor formation in the DMH+DSS-induced IBD model, but also improved the survival rate, indicating that anti-inflammatory activity is one of the mechanisms for the antitumor effects of PSK.

References

  1. Virchows Arch. 2002 Jul;441(1):1-11 - PubMed
  2. Lancet. 2007 May 12;369(9573):1603-13 - PubMed
  3. N Engl J Med. 2007 May 24;356(21):2131-42 - PubMed
  4. Br J Cancer. 2004 Mar 8;90(5):1003-10 - PubMed
  5. Cancer Sci. 2006 Jun;97(6):439-47 - PubMed
  6. Cancer Immunol Immunother. 1995 Mar;40(3):152-6 - PubMed
  7. Circ Res. 2004 May 14;94(9):1186-94 - PubMed
  8. Anticancer Res. 2002 May-Jun;22(3):1737-54 - PubMed
  9. Lancet Oncol. 2001 Sep;2(9):533-43 - PubMed
  10. Gastroenterology. 1999 May;116(5):1063-71 - PubMed
  11. J Exp Med. 2006 Jun 12;203(6):1391-7 - PubMed
  12. N Engl J Med. 2006 Aug 31;355(9):885-95 - PubMed
  13. Int J Cancer. 1997 Jan 27;70(3):362-72 - PubMed
  14. Shock. 2006 Jan;25(1):36-42 - PubMed
  15. Gastroenterology. 2004 Feb;126(2):451-9 - PubMed
  16. Lab Invest. 1993 Aug;69(2):238-49 - PubMed
  17. Cell. 2004 Aug 6;118(3):285-96 - PubMed
  18. Am J Gastroenterol. 2005 Jun;100(6):1345-53 - PubMed
  19. Cancer Immunol Immunother. 1998 Aug;46(6):338-44 - PubMed
  20. Lymphokine Res. 1990 Winter;9(4):475-83 - PubMed
  21. Cancer Sci. 2005 Feb;96(2):69-76 - PubMed
  22. J Exp Clin Cancer Res. 2001 Sep;20(3):413-8 - PubMed
  23. Science. 2006 Oct 13;314(5797):268-74 - PubMed
  24. Lancet. 2009 Apr 11;373(9671):1301-9 - PubMed
  25. N Engl J Med. 2006 Aug 31;355(9):873-84 - PubMed
  26. J Gastroenterol Hepatol. 2002 Oct;17(10):1078-83 - PubMed
  27. Cancer Treat Rev. 1984 Jun;11(2):131-55 - PubMed
  28. Gastroenterology. 1990 Mar;98(3):694-702 - PubMed
  29. Cancer Immunol Immunother. 1995 Dec;41(6):389-96 - PubMed
  30. Nature. 2004 Sep 23;431(7007):461-6 - PubMed

Publication Types